In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci

Annals of Clinical Microbiology and Antimicrobials

Volumn 4, Issue , 2005, Pages

  El Azizi, Mohamed ^a   Rao, Suma ^a   Kanchanapoom, Termkiat ^a   Khardori, Nancy ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biofilm; Disrupted biofilm; Linezolid; Quinupristin dalfopristin; Vancomycin

Indexed keywords

DALFOPRISTIN; LINEZOLID; METICILLIN; QUINUPRISTIN; VANCOMYCIN; ACETAMIDE DERIVATIVE; DALFOPRISTIN PLUS QUINUPRISTIN; OXAZOLIDINONE DERIVATIVE; QUINUPRISTIN-DALFOPRISTIN; VIRGINIAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BIOFILM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; IN VITRO STUDY; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS; STAPHYLOCOCCUS EPIDERMIDIS; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; BIOFILMS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 26444556065     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-4-2     Document Type: Article

References (41)

1. Remington JS: Introduction. Clin Infect Dis 2000, 31(Suppl 4):S123.
2. von Eiff C, Heilmann C, Herrmann M, Peters G: Basic aspects of the pathogenesis of staphylococcal polymer associated infections. Infection 1999, 27(Suppl 1):S7-10.
3. Khardori N, Yassien M, Wilson K: Tolerance of Staphylococcus epidermidis grown from indwelling vascular catheters to antimicrobial agents. J Ind Microbiol 1995, 15:148-151.
4. Costerton JW: Introduction to biofilm. Int J Antimicrob Agents 1999, 11:217-221.
5. Costerton JW, Stewart P, Greenberg E: Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
6. Donlan RM, Costerton JW: Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002, 15:167-193.
7. Gross M, Cramton SE, Götz F, Peschel A: Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun 2001, 69:3423-3426.
8. Jansen B: Current approaches to the prevention of catheter-related infections. In In Catheter-related infections Edited by: Seifert H, Jansen B, Farr BM. New York: Marcel Dekker Inc; 1997:441-446.
9. Crnich CJ, Maki DG: The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002, 34:1232-1242.
10. Marr KA: Staphylococcus aureus bacteremia in patients undergoing hemodialysis. Semin Dial 2000, 13:23-29.
11. Stewart PS, Costerton JW: Antibiotic resistance in biofilms. Lancet 2001, 358:135-138.
12. Curtin J, Cormican M, Fleming G, Keelehan J, Colleran E: Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections. Antimicrob Agents Chemother 2003, 47:3145-3148.
13. Dunne WM Jr: Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev 2002, 15:155-166.
14. Anwar H, Strap JL, Chen K, Costerton JW: Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin. Antimicrob Agents Chemother 1992, 36:1208-1214.
15. Duguid IG, Evans E, Brown MR, Gilbert P: Effect of biofilm culture upon the susceptibility of Staphylococcus epidermidis to tobramycin. J Antimicrob Chemother 1992, 30:803-810.
16. +2, and HEPES-treated Pseudomonas aeruginosa biofilms. Can J Microbiol 1992, 38:1214-1218.
17. Suci PA, Mittelman MW, Yu FP, Geesey GG: Investigation of ciprofloxacin penetration into Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 1994, 38:2125-2133.
18. Dagostino L, Goodman AE, Marshall KC: Physiological responses induced in bacteria adhering to surfaces. Biofouling 1991, 15:113-119.
19. Adams JL, McLean RJ: Impact of rpoS deletion on Escherichia coli biofilms. Appl Environ Microbiol 1999, 65:4285-4287.
20. Chuard C, Vaudaux P, Waldvogel FA, Lew D: Susceptibility of Staphylococcus aureus growing on fibronectin-coated surfaces to bactericidal antibiotics. Antimicrob Agents Chemother 1993, 37:625-632.
21. Souli M, Giamarellou H: Effects of slime produced by clinical isolates of coagulase-negative staphylococci on activities of various antimicrobial agents. Antimicrob Agents Chemother 1998, 42:939-941.
22. Cramton SE, Ulrich M, Götz F, Doring G: Anaerobic conditions induce expression of Polysaccharide intracellular adhesion in Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun 2001, 69:4079-4085.
23. Götz F: Staphylococcus and biofilms. Mol Microbiol 2002, 43:1367-1378.
24. Khardori N, Yassien M: Biofilms in device-related infections. J Ind Microbiol 1995, 15:141-147.
25. Khardori N, Wong E, Nguyen H, Jeffery-Wiseman C, Wallin E, Tewari RP, Bodey GP: Effect of subinhibitory concentrations of clindamycin and trospectomycin on the adherence of Staphylococcus epidermidis in an in vitro model of vascular catheter colonization. J Infect Dis 1991, 164:108-113.
26. Yassien M, Khardori N, Ahmedy A, Toama M: Modulation of biofilms of Pseudomonas aeruginosa by quinolones. Antimicrob Agents Chemother 1995, 39:2262-2268.
27. Yassien M, Khardori N: Interaction between biofilms formed by Staphylococcus epidermidis and quinolones. Diagn Microbiol Infect Dis 2001, 40:79-89.
28. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF: Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces. Antimicrob Agents Chemother 2003, 47:3407-3414.
29. National Committee for Clinical Laboratory Standards: Method for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard-Sixth edition NCCLS document M7-A6 Wayne, Pennsylvania, USA, NCCLS 2003.
30. Roslev P, King GM: Application of a tetrazolium salt with a water-soluble formazan as an indicator of viability in respiring bacteria. Appl Environ Microbiol 1993, 59:2891-2896.
31. Lowy FD: Staphylococcus aureus infections. N Engl J Med 1998, 339:520-532.
32. Moellering RC Jr: Problems with antimicrobial resistance in gram-positive cocci. Clin Infect Dis 1998, 26:1177-1178.
33. Boyce JM: Epidemiology and prevention of nosocomial infections. In In The staphylococci in human disease Edited by: Crossly KB, Archer GL. New York Churchill Livingstone; 1997:309-329.
34. Steinberg JP, Clark CC, Hackman BO: Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin Infect Dis 1996, 23:255-259.
35. Mah TF, O'Toole GA: Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbial 2001, 9:34-39.
36. Potera C: Forging a link between biofilms and disease. Science 1999, 283:1837-1839.
37. Pratt LA, Kolter R: Genetic analyses of bacterial biofilm formation. Curr Opin Microbial 1999, 2:598-603.
38. Gander S, Finch R: The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria. J Antimicrob Chemothe 2000, 46:61-67.
39. Nickel JC, Ruseska I, Wright JB, Costerton JW: Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob Agents Chemother 1985, 27:619-624.
40. Hamilton-Miller JM, Shah S: Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. J Antimicrob Chemother 1997, 39(Suppl A): 103-108.
41. Wilcox MH, Kite P, Mills K, Sugden S: In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm. J Antimicrob Chemother 2001, 47:171-175.